PharmaCyte Cash vs Common Stock Total Equity Analysis
| PMCB Stock | USD 2.09 0.03 1.42% |
PharmaCyte Biotech financial indicator trend analysis is much more than just breaking down PharmaCyte Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PharmaCyte Biotech is a good investment. Please check the relationship between PharmaCyte Biotech Cash and its Common Stock Total Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.
Cash vs Common Stock Total Equity
Cash vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PharmaCyte Biotech Cash account and Common Stock Total Equity. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between PharmaCyte Biotech's Cash and Common Stock Total Equity is -0.64. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of PharmaCyte Biotech, assuming nothing else is changed. The correlation between historical values of PharmaCyte Biotech's Cash and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of PharmaCyte Biotech are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Cash i.e., PharmaCyte Biotech's Cash and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | -0.64 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Cash
Cash refers to the most liquid asset of PharmaCyte Biotech, which is listed under current asset account on PharmaCyte Biotech balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from PharmaCyte Biotech customers. The amounts must be unrestricted with restricted cash listed in a different PharmaCyte Biotech account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from PharmaCyte Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PharmaCyte Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.At present, PharmaCyte Biotech's Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 2.44, whereas Selling General Administrative is forecasted to decline to about 4.7 M.
PharmaCyte Biotech fundamental ratios Correlations
Click cells to compare fundamentals
PharmaCyte Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PharmaCyte Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 816.6K | 552.5K | 499.0K | 458.3K | 527.0K | 467.7K | |
| Total Current Liabilities | 1.0M | 724.8K | 704.4K | 586.6K | 674.6K | 1.2M | |
| Total Stockholder Equity | 5.1M | 6.7M | 89.9M | 72.7M | 83.6M | 87.8M | |
| Retained Earnings | (103.9M) | (107.4M) | (111.6M) | (116.0M) | (104.4M) | (99.1M) | |
| Common Stock Total Equity | 101.3K | 118.6K | 163.9K | 159.0 | 182.85 | 173.71 | |
| Common Stock Shares Outstanding | 1.4B | 1.7B | 15.5M | 19.5M | 22.4M | 21.3M | |
| Other Stockholder Equity | 108.8M | (20.4K) | 201.6M | 188.7M | 217.0M | 227.8M | |
| Total Liab | 1.1M | 724.8K | 704.4K | 586.6K | 674.6K | 640.8K | |
| Common Stock | 163.9K | 159.0 | 2.1K | 2.2K | 2.5K | 2.4K | |
| Total Assets | 6.2M | 7.4M | 90.6M | 73.3M | 84.3M | 88.5M | |
| Net Debt | (819.7K) | (2.2M) | (85.4M) | (68.0M) | (61.2M) | (58.2M) | |
| Accounts Payable | 185.8K | 172.3K | 205.4K | 128.3K | 147.5K | 140.1K | |
| Cash | 894.9K | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Cash And Short Term Investments | 2.5M | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Liabilities And Stockholders Equity | 6.2M | 7.4M | 90.6M | 73.3M | 84.3M | 88.5M | |
| Total Current Assets | 1.0M | 2.3M | 85.5M | 68.1M | 78.4M | 82.3M | |
| Other Current Assets | (1.4M) | 73.1K | 94.2K | 107.7K | 96.9K | 92.1K | |
| Accumulated Other Comprehensive Income | (21.7K) | (20.4K) | (15.8K) | (23.0K) | (26.5K) | (27.8K) | |
| Net Tangible Assets | 1.5M | 1.5M | 3.1M | 86.4M | 99.3M | 104.3M | |
| Net Invested Capital | 5.2M | 6.7M | 89.9M | 72.7M | 83.6M | 87.8M | |
| Net Working Capital | 6.2K | 1.6M | 84.8M | 67.6M | 77.7M | 81.6M | |
| Capital Stock | 163.9K | 159.0 | 2.1K | 2.2K | 1.9K | 1.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.